Methods of treating autoimmune disease using a domain antibody directed against CD40L

US11466091B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Marek Honczarenko · Princeton, US
• Vaishali Shah · Pennington, US
• Lixin Lang · North Potomac, US
• Urvi Ashish ARAS · Kendall Park, US
• Diane E. Shevell · Westfield, US
• Christine Kratt · Fort Collins, US
• Karen Price · Sauquoit, US
• Suzanne J. Suchard · Wilmington, US

Key dates

• Filing date: Feb 20, 2020
• Grant date: Oct 11, 2022
• Expiry date: Jul 2, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.